Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (NASDAQ: TWST) is a synthetic biology and biotechnology company whose news flow reflects its focus on synthetic DNA tools, silicon-based DNA synthesis and research-enabling technologies. Company announcements frequently describe Twist as a mid-cap growth and value biotech company serving customers in medicine, agriculture, industrial chemicals and defense, where its DNA-based products support research and development programs.
On this page, readers can follow TWST news related to product launches, collaborations, financial updates and corporate developments. Recent press releases have highlighted the launch of research-grade plasmid DNA preps for nucleic acid therapeutics research, including animal origin-free and transfection-grade options with specific quality attributes and target yields. Other announcements cover expanded collaborations, such as the Trinity Freestyle Fast Hybridization workflow developed with Element Biosciences for the AVITI sequencing platforms.
Investors and researchers can also track earnings-related news, including preliminary revenue updates, quarterly and full-year financial results, and associated conference calls and webcasts. Corporate governance and compensation updates, such as inducement equity grants under Nasdaq Listing Rule 5635(c)(4), appear in Twist’s news stream as well.
In addition, Twist publishes news on biosecurity and policy engagement, including participation in a Science paper examining biosecurity screening practices in AI-assisted protein design. Conference presentations at major healthcare and life science events are also regularly announced. For anyone following TWST stock or the evolution of synthetic DNA technologies, this news page provides a centralized view of Twist Bioscience’s public communications and key milestones.
Twist Bioscience Corporation (NASDAQ: TWST) has successfully closed its public offering of 3,211,362 shares at $110.00 each, generating approximately $323.7 million in net proceeds. The offering included shares sold by both the company and certain selling stockholders. Twist plans to utilize these funds to enhance operational capacity, increase R&D investments, and expand its manufacturing capabilities for its synthetic DNA offerings. Additionally, a portion of the proceeds may be allocated towards acquiring complementary businesses.
Twist Bioscience Corporation (NASDAQ: TWST) has priced a public offering of 2,802,272 shares of common stock at $110.00 per share, aiming for approximately $300 million in gross proceeds. The offering includes 2,727,272 shares sold by Twist and 75,000 shares from selling stockholders. Expected to close on December 7, 2020, funds will enhance operational capacity, R&D, and IT infrastructure, with potential investments in complementary businesses. The offering is underwritten by J.P. Morgan, Goldman Sachs, Cowen, and Evercore.
Twist Bioscience Corporation (NASDAQ: TWST) announced its intention to conduct an underwritten public offering of up to $250 million in common stock. Additionally, certain selling stockholders plan to offer 75,000 shares. The offering includes a 30-day option for underwriters to purchase up to $37.5 million more. Twist aims to utilize net proceeds to enhance operational capacity, invest in automation and R&D, and support growth in various sectors, including NGS and DNA data storage.
Twist Bioscience Corporation (NASDAQ: TWST) announced its participation in two upcoming virtual investor conferences. Emily Leproust, CEO, and Jim Thorburn, CFO, will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on November 30 at 8:00 a.m. ET, and the Evercore ISI HealthCONx Conference on December 1 at 1:50 p.m. ET. Both presentations can be accessed on the company’s investor relations website, with replays available for 90 days post-event. Twist Bioscience specializes in synthetic DNA products and applications across multiple industries, including healthcare and agriculture.
Twist Bioscience reported strong financial results for fiscal year 2020 with total revenues increasing to $90.1 million from $54.4 million in fiscal 2019. Total orders rose to $116.7 million. Despite the growth, the company experienced a net loss of $139.9 million, or $3.57 per share. The fourth quarter also saw revenue growth to $32.4 million from $15.7 million year-over-year. With a strong cash position of $290 million, Twist plans aggressive growth in fiscal 2021, focusing on synthetic biology, NGS, and biopharma technologies.
Twist Bioscience Corporation (Nasdaq: TWST) announced promising preclinical data for three proprietary antibodies targeting the S1 protein of SARS-CoV-2. The antibodies, TB202-3 and TB202-63, demonstrated protection against weight loss in a hamster model at a low dose of 1 mg/kg. TB181-36, discovered in collaboration with Vanderbilt University, also showed protective effects at doses of 5 mg/kg and 10 mg/kg. These results suggest potential for new COVID-19 treatment approaches, including a preventive nasal spray, amid rising global infection cases.
Twist Bioscience (TWST) and Biotia have launched the SARS-CoV-2 Next-Generation Sequencing (NGS) Assay, a new research tool for COVID-19 sequencing and surveillance. This highly sensitive assay allows for extensive monitoring of the virus's genetic changes, surpassing standard PCR tests in capability. Validated on a NextSeq® sequencer, the assay provides crucial sequence data to aid researchers in tracking mutations and understanding the virus's evolution. The assay targets various sample types, offering public health insights, particularly during ongoing pandemic waves.
Twist Bioscience Corporation (NASDAQ: TWST) has launched the Comprehensive Viral Research Panel, a next-generation sequencing (NGS) tool that identifies over 3,000 viral genomes. This panel aims to assist in detecting new viral species and supports metagenomic surveillance. It features over one million unique probes and integrates with the One Codex analysis platform for streamlined results. The product is designed for research use only and contributes to public health efforts in monitoring viral diseases.
Twist Bioscience (TWST), along with Illumina (ILMN), Western Digital (WDC), and Microsoft, has formed a strategic alliance to advance DNA data storage. This coalition aims to create an industry roadmap for interoperability and commercial solutions as demand for archival storage surges due to data growth. DNA's durability and density—storing massive amounts of data in minimal space—position it as a viable alternative to traditional storage. The alliance anticipates that by 2024, 30% of digital businesses will initiate DNA storage trials, addressing the urgent need for long-term solutions.
Twist Bioscience Corporation (NASDAQ: TWST) will announce its financial results for the fiscal 2020 fourth quarter and full year on November 23, 2020, before market opening. A conference call at 8:00 a.m. ET will discuss these results and provide a business update. Investors can access the financial release via the Investor Relations section on the company's website. Twist Bioscience focuses on synthetic DNA manufacturing using a proprietary silicon platform, catering to various industries including healthcare and agriculture.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
